VIDEO: Low-dose colchicine can address residual inflammatory risk
Click Here to Manage Email Alerts
Key takeaways:
- Patients with elevated levels of high-sensitivity C-reactive protein are at risk for CV events.
- Low-dose colchicine can address residual inflammatory risk in high-risk patients on statin therapy.
BOSTON — In this Healio video exclusive, Paul M. Ridker, MD, MPH, discusses the use of low-dose colchicine to target inflammation in patients who remain at high CVD risk despite controlled LDL.
Ridker gave a presentation on low-dose colchicine for chronic atherosclerosis as an adjunct to statin therapy at the Cardiometabolic Health Congress. As Healio previously reported, the FDA in June approved colchicine 0.5 mg (Lodoco, Agepha Pharma) for reduction of CV events in patients with atherosclerotic CVD or multiple CV risk factors who have residual inflammatory risk, as determined by elevated levels of high-sensitivity C-reactive protein.
“We’ve shown repeatedly that high-sensitivity CRP levels predict risk in fact greater than LDL cholesterol,” said Ridker, the Eugene Braunwald Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School.
Watch the video for more.
Reference:
- Ridker PM. Session II: Dyslipidemia/atherosclerosis/thrombosis. Presented at: Cardiometabolic Health Congress; Oct. 18-21, 2023; Boston.
Collapse
Healio Interviews
Click Here to Manage Email Alerts